Skip to main content
. 2014 Aug 13;5(18):8614–8624. doi: 10.18632/oncotarget.2345

Figure 3. Selective access to tumor vasculature using PE-conjugated ME-9F1 mAb.

Figure 3

(A) Representative LSCM images of selective arterial blood supply to HCC. Alexa Fluor 488 (green)- or PE (red)-labeled ME-9F1 mAb were injected during alternate clamping of the hepatic artery or portal vein. Blood vessels in the liver, as well as in small tumors, were labeled with both Alexa Fluor 488 and PE (mixed arterial and portal blood supply). Microvessels in larger tumors were labeled mainly with PE-conjugated mAb (selective arterial blood supply). (B–D) Selective enrichment of labeled ME-9F1 mAb using bioavailability blockade of nontumoral epitopes or/and intra-arterial injection. Diagrams show mAb content in the tumor, liver (C), and lung (E) and the mAb tumor:liver ratio (D). Bioavailability blockade of nontumoral epitopes by unconjugated mAb and intra-arterial injection of 10 ng/g BW mAb improved selective accumulation of labeled mAb in tumor tissue and strongly reduced mAb load in the lung. *Indicates significant differences between tumor and liver tissue. (E) LSCM images of different organs without and with blockade of nontumoral epitopes. Blockade of nontumoral epitopes resulted in visualization of solid tumors (>5mm) through selective labeling of tumor vasculature, whereas the fluorescence signal in the liver and other organs was strongly inhibited after blockade.